Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary provides mixed signals: a 12% revenue increase and reduced net loss are positive, but increased G&A expenses and a lack of strategic updates or shareholder returns are concerning. The Q&A section offers no additional insights. Overall, the financial improvements balance the uncertainties, resulting in a neutral sentiment.
Key Financial Performance
Revenue Altimmune reported revenue of $15.2 million for Q1 2026, which represents a 12% increase year-over-year. This growth was primarily driven by increased demand for their flagship product.
Net Loss The company reported a net loss of $8.5 million for Q1 2026, compared to a net loss of $10.3 million in Q1 2025. This improvement was attributed to cost-saving measures and operational efficiencies.
Research and Development Expenses R&D expenses were $6.8 million in Q1 2026, down 5% from $7.2 million in Q1 2025. The decrease was due to the completion of certain clinical trials.
General and Administrative Expenses G&A expenses increased to $4.5 million in Q1 2026, up 15% from $3.9 million in Q1 2025. The rise was attributed to higher personnel costs and expanded administrative activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Altimmune cautions that forward-looking statements are subject to risks and uncertainties, which could impact the company's future expectations, plans, and prospects.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Altimmune
Anupam Damani
Asset LP
Blair LLC
CEO President
Chairman CEO
Chief
Damani Goldman
Devarakonda Truist
Division Annabel
Division Anupam
Division DiFiore
Division Jiale
Division Jonathan
Division Srikripa
Division Tsan
Division Wood
EDT Jerome
Eliana Merle
Financial
Hsieh Blair
Inc Research
Jerome Durso
Jiale Song
Jonathan Wolleben
LP lady
Merle Barclays
Officer Eliana
Officer Gregory
President Christophe
President Investor
Relations expectation
Sachs Asset
Sanay Vice
Securities Inc
ALT Transcript
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call summary provides mixed signals: a 12% revenue increase and reduced net loss are positive, but increased G&A expenses and a lack of strategic updates or shareholder returns are concerning. The Q&A section offers no additional insights. Overall, the financial improvements balance the uncertainties, resulting in a neutral sentiment.
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Positive3-5
The company's strategic plan highlights strong clinical progress, particularly with pemvidutide's development in MASH and AUD, and positive market research in Europe. The Q&A session revealed no major negative concerns, and the company has a solid financial runway. The FDA's cautious stance on NITs as endpoints is a minor setback but does not overshadow the overall positive sentiment. The absence of market cap data limits the prediction's precision, but the strategic advancements suggest a positive stock price movement.
ALT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
